- •Phase I study of sequential extended field ChemoRT and combination chemotherapy
- •Phase I study for primary therapy of para-aortic node positive cervical cancer
- •Adjuvant chemotherapy in the primary management of advanced cervical cancer
- •Safety and feasibility of paclitaxel and carboplatin after extended field RT
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Cancer statistics, 2017.CA Cancer J. Clin. 2017; 67: 7-30
- Accuracy of 18-fluoro-2-deoxy-d-glucose positron emission tomography in the pretherapeutic detection of occult para-aortic node involvement in patients with a locally advanced cervical carcinoma.Ann. Surg. Oncol. 2011; 18: 2302-2309
- Treatment outcomes and prognostic factors in uterine cervical cancer patients treated with postoperative extended field radiation therapy.Gynecol. Oncol. 2009; 20: 227-231
- Cervical carcinoma metastatic to para-aortic nodes: extended field radiation therapy with concomitant 5-fluorouracil and cisplatin chemotherapy: a Gynecologic Oncology Group study.Int. J. Radiat. Oncol. Biol. Phys. 1998; 42: 1015-1023
- Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01.J. Clin. Oncol. 2004; 22: 872-880
- Chemotherapy and extended-field radiation therapy to para-aortic area in patients with histologically proven metastatic cervical cancer to para-aortic nodes: a phase II pilot study.Gynecol. Oncol. 1994; 52: 326-331
- High-dose extended-field irradiation and high-dose-rate brachytherapy with concurrent chemotherapy for cervical cancer with positive para-aortic lymph nodes.Int. J. Radiat. Oncol. Biol. Phys. 2009; 74: 1522-1528
- Extended-field irradiation and intracavitary brachytherapy combined with cisplatin chemotherapy for cervical cancer with positive para-aortic or high common iliac lymph nodes: results of ARM 1 of RTOG 0116.Int. J. Radiat. Oncol. Biol. Phys. 2007; 68: 1081-1087
- Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix.J. Clin. Oncol. 2011; 29: 1678-1685
- A phase I/II study of extended field radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in patients with cervical carcinoma metastatic to the para-aortic lymph nodes: a Gynecologic Oncology Group study.Gynecol. Oncol. 2009; 112: 78-84
- Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study.J. Clin. Oncol. 2004; 22: 3113-3119
- Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study.J. Clin. Oncol. 2005; 23: 4626-4633
- Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study.J. Clin. Oncol. 2009; 27: 4649-4655
- Improved survival with bevacizumab in advanced cervical cancer.N. Engl. J. Med. 2014; 370: 734-743
- Carboplatin and paclitaxel in metastatic or recurrent cervical cancer.Int. J. Gynecol. Cancer. 2009; 19: 777-781
- Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized Phase III Trial JCOG0505.J. Clin. Oncol. 2015; 33: 2129-2135
- New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).Eur. J. Cancer. Jan 2009; 45: 228-247
- Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: results from the phase Ib KEYNOTE-028 trial.J. Clin. Oncol. 2017; 35: 4035-4041
☆This study was supported by National Cancer Institute grants to the Gynecologic Oncology Group (GOG) Administrative Office ( CA 27469 ) and the Gynecologic Oncology Group Statistical Office ( CA 37517 ) and National Cancer Institute grants to NRG Oncology SDMC grant U10 CA180822 and the NRG Oncology Operations grant U10CA 180868 .
☆The following Gynecologic Oncology Group member institutions participated in the primary treatment studies: University of Oklahoma Health Sciences Center, Case Western Reserve University, Women and Infants Hospital, and the Hospital of Central Connecticut.